Investing.comCodex · 实盘不做把握 5/10不做原因:消息已过时
北京时间·🕒 发布 08-05 20:36:37时区推断·⟳ 抓取 08-05 20:37:45·⚡ 决策 08-26 16:33:20 +20d19h·62.2 天前
Schrödinger宣布与BMS扩大合作，在BMS研发组织部署AI药物发现工具Bunsen
事件为正面商业化验证，但已明显过期、扩散充分、无披露金额，且缺少真实行情与事件研究工具支持，不能形成当前可执行交易。
📄 原文Investing.com↗ 原文
Schrödinger expands partnership with Bristol Myers Squibb
Our AI knew it: This high-conviction medtech just jumped 27%+ on blowout earnings NEW YORK - Schrödinger, Inc. (NASDAQ:…
不做 Schrödinger, Inc.（SDGR.US）
不做Schrödinger（SDGR.US）：合作方向正面，但事件已过期约21天、金额未披露、同日财报混杂，且未能取得真实行情和event_study来形成可执行入场边界。
不做 Bristol Myers Squibb（BMY.US）
不做Bristol Myers Squibb（BMY.US）：作为大型药企采购方，单一研发软件部署对短线收入利润影响不可量化，缺少正期望交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Schrödinger的一手IR确认BMS将部署Bunsen，说明其AI药物发现平台获得大型药企进一步采用；但该消息首发于2026-08-05，当前为2026-08-26，已超过20天，同日还伴随Q2财报和指引信息，短线价格反应难以归因；协议未披露金额，无法估算对软件ACV、收入或市值的可交易增量，因此不下单。
消息传播链
- 公司正式宣布与BMS签署战略合作和软件协议，在BMS研发组织部署Bunsen。
- Investing.com转述公司新闻稿，未新增金额或业绩指引信息。
- 公司Q2财报将Bunsen早期版本发布和BMS软件协议列入近期亮点，同时披露全年ACV指引。
- 行业媒体继续报道该合作，说明消息已进入行业传播层。
关键理由
- BMS为Schrödinger长期客户，本次部署Bunsen有助于验证其AI+物理计算药物发现平台的大客户采用路径。
- Schrödinger同日财报披露Q2 ACV为2960万美元、同比增长27%，并将BMS协议列为近期亮点，但没有披露该协议的独立金额。
- 量级句：Schrödinger 2026全年ACV指引为2.18亿至2.28亿美元，本次BMS协议未披露新增ACV或收入金额，因此无法估算本事件相对收入、利润或市值的增量占比。
主要风险
- 消息已在2026-08-05由公司IR、Business Wire和多家媒体传播，当前研判时点已显著滞后，price-in风险高。
- 协议属于软件部署和功能共研，未披露最低采购额、付费席位、合同期限或收入确认安排，短线业绩弹性无法量化。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-05 · 影响 weakens
一手公告和财报均未披露合同金额、ACV贡献或收入确认节奏，削弱短线可交易量级。
检索:Schrödinger BMS Bunsen agreement amount revenue ACV August 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-05 · 影响 weakens
BMS合作与Q2财报同日披露，价格反应会混入ACV增长、净利润转正和全年指引等因素，难以归因到单一合作催化。
检索:SDGR Bunsen BMS Q2 2026 earnings same day 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使本次不能从正面业务信号升级为可执行ENTER。
方向:未取得可用event_study结果；仅从事件性质看，客户部署通常偏正面，但协议金额未披露时短线胜率和幅度无法校准。
涨幅量级:没有高相似、锚点干净且已测算的先例，不能用先例设定tp/sl。
形态:无法确认是否存在反复见光死模式；当前更主要的问题是事件已过期且与同日财报混杂。
原文全文
展开原文 · 2,083 字
Our AI knew it: This high-conviction medtech just jumped 27%+ on blowout earnings
NEW YORK - Schrödinger, Inc. (NASDAQ:SDGR) announced today a strategic agreement with Bristol Myers Squibb to deploy its AI platform Bunsen within BMS’s research organization, according to a press release statement.
The agreement expands an existing partnership between the two companies. BMS will use Bunsen, described as an agentic AI co-scientist, alongside Schrödinger’s computational platform and RetroSynth synthesis planning platform.
Bunsen is designed to execute Schrödinger’s physics-based computational platform by planning and running molecular discovery workflows and interpreting results. The system differs from general-purpose agents by being optimized specifically for Schrödinger’s validated computational methods.
Under the agreement, Schrödinger will collaborate with BMS scientists on developing functionality within Bunsen for large-scale chemical exploration.
"BMS is a long-standing customer and collaborator, and they have been an industry leader in integrating computation into drug discovery," said Robert Abel, Chief Scientific Officer, Platform, of Schrödinger.
Stephen Johnson, Vice President, Computational Sciences at Bristol Myers Squibb, stated: "Bunsen is another capability we are adding to that toolkit, one that allows our scientists to think differently about how physics-based tools can be used to navigate molecular design space and accelerate the discovery of innovative medicines for patients."
Schrödinger’s software platform is built on over 30 years of research and development and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions globally. The company also maintains its own portfolio of collaborative and proprietary programs.
The press release included forward-looking statements regarding the potential advantages of the computational platform and expectations for Bunsen’s deployment at BMS.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK - Schrödinger, Inc. (NASDAQ:SDGR) announced today a strategic agreement with Bristol Myers Squibb to deploy its AI platform Bunsen within BMS’s research organization, according to a press release statement.
The agreement expands an existing partnership between the two companies. BMS will use Bunsen, described as an agentic AI co-scientist, alongside Schrödinger’s computational platform and RetroSynth synthesis planning platform.
Bunsen is designed to execute Schrödinger’s physics-based computational platform by planning and running molecular discovery workflows and interpreting results. The system differs from general-purpose agents by being optimized specifically for Schrödinger’s validated computational methods.
Under the agreement, Schrödinger will collaborate with BMS scientists on developing functionality within Bunsen for large-scale chemical exploration.
"BMS is a long-standing customer and collaborator, and they have been an industry leader in integrating computation into drug discovery," said Robert Abel, Chief Scientific Officer, Platform, of Schrödinger.
Stephen Johnson, Vice President, Computational Sciences at Bristol Myers Squibb, stated: "Bunsen is another capability we are adding to that toolkit, one that allows our scientists to think differently about how physics-based tools can be used to navigate molecular design space and accelerate the discovery of innovative medicines for patients."
Schrödinger’s software platform is built on over 30 years of research and development and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions globally. The company also maintains its own portfolio of collaborative and proprietary programs.
The press release included forward-looking statements regarding the potential advantages of the computational platform and expectations for Bunsen’s deployment at BMS.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。